21
total announcements
500660.BO · 15 min delayed
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has issued a corrigendum to its postal ballot notice dated August 3, 2026, correcting a typographical error in the basic salary figure of Mr. Akshikar. The corrigendum is available on the company's website, stock exchanges, and KFin Technologies Limited's e-voting website.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has issued a corrigendum to its postal ballot notice dated August 3, 2026, correcting a typographical error in the basic salary figure of Mr. Akshikar.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd clarifies significant increase in volume, stating it's market-driven and assures compliance with listing regulations.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has received a clarification request from the exchange regarding a sudden movement in trading volume on August 26, 2026. The company is expected to respond to the query.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has received an intimation from the Income Tax Department for a refund of Rs 4.99 Crores for the assessment year 2025-2026.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has completed the dispatch of the Postal Ballot Notice to all members whose name appears on the Register of Members/List of Beneficial Owners as on Friday, 7th August 2026. The notice is related to the appointment of Ms. Karine J F Natland as a Non-Executive Director and the re-appointment of Mr. Bhushan Akshikar as Managing Director. The voting process will commence on 14th August 2026 and end on 13th September 2026.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has announced a postal ballot notice for the appointment of a non-executive director and re-appointment of the managing director through remote e-voting.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd announced its Q1 FY 2027 earnings call, with Managing Director Mr. Bhushan Akshikar and Chief Financial Officer Mr. Rononjit Biswas presenting the results. The company reported a 13.5% industry growth, with a balanced mix of volume, price, and new introductions. GlaxoSmithKline's portfolio showed a significant presence in therapy areas such as anti-infectives, pain, respiratory, nutritional supplements, vitamins, dermatologicals, and hormones and vaccines, which all grew double-digit. The company's growth was balanced across geographies, including metros, Tier 1 cities, Tier 2 and rural markets, and among specialists, super specialists, and general practitioners.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has received a refund of Rs 52 crores from the ACIT Cir 7(1)(1) after a CIT-Appeal for the assessment year 1984-85.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has uploaded the recording of an analyst/institutional investor meeting on its website, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹92.44 crore and net profit at ₹25.33 crore. The company has also appointed Mr. Ronak Shah as Associate Fund Manager - Fixed Income, effective August 3, 2026.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has announced the outcome of its analyst/institutional investor meetings, with the recording available on its website.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has announced the reappointment of Mr. Bhushan Akshikar as Managing Director for a term of two years from 1st December 2026. The company has also announced the appointment of Ms. Karine J F Natland as a Non-Executive Director. The company has also released its unaudited standalone and consolidated financial results for the first quarter ended 30th June 2026.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has announced the resignation of Non-Executive Director Mr. Subesh Williams and the appointment of Ms. Karine J F Natland as Non-Executive Director. The company has also re-appointed Mr. Bhushan Akshikar as Managing Director for a term of two years. The company has released its unaudited standalone and consolidated financial results for the first quarter ended 30th June 2026.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd announced changes in its Board of Directors, including the stepping down of Mr. Subesh Williams and the appointment of Ms. Karine J F Natland as a Non-Executive Director. The company also re-appointed Mr. Bhushan Akshikar as a Managing Director. The announcement includes the company's unaudited standalone and consolidated financial results for the first quarter ended 30th June 2026.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd announced its Q1FY27 financial results, with revenue at INR 924 crores, up 15% Y-o-Y, and Profit After Tax (PAT) increasing by 24% to INR 253 crores. The company's General Medicines portfolio grew strongly, with key promoted brands outperforming the market. The Vaccines business also grew, driven by continued leadership in the self-pay private paediatric vaccines market and stronger endorsement from the healthcare professional community.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has announced its Q1 FY27 results, with revenue growing 15% YoY to ₹924cr, EBITDA margin expanding 50bps to 31.7%, and PAT margin increasing 200bps to 27.6%. The company's key brands maintained their competitive performance in the market, with Gen Meds and Vx portfolios leading the growth.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has announced its Q1 FY2027 results, with revenue from operations at Rs. 92442 lakhs and profit before exceptional items and tax at Rs. 33798 lakhs. The company has also announced the re-appointment of Mr. Bhushan Akshikar as Managing Director and the appointment of Ms. Karine J F Natland as Non-Executive Director.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd announced its Q1 FY2026 financial results, with revenue from operations at Rs. 92442 lakhs, and profit before exceptional items and tax at Rs. 33798 lakhs. The company also announced the re-appointment of Mr. Bhushan Akshikar as a Managing Director and the appointment of Ms. Karine J F Natland as a Non-Executive Director. Mr. Subesh Williams stepped down from the Board.
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd has scheduled an analyst/institutional investor meeting on August 3rd, 2026, to share information already in the public domain.